Literature DB >> 11416606

Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals.

George L. Bakris1.   

Abstract

Current recommendations by the Sixth Report of Joint National Committee (JNC) suggest that lower blood pressure levels than previously recommended should be obtained in order to preserve renal function and reduce cardiovascular risk. This holds true for people with diabetes as well as those with renal insufficiency. By all accounts, we as a nation are doing a poor job of even achieving the general guideline for blood pressure control (i.e., less than 140/90 mm Hg). This has contributed to a plateau in mortality reduction from cardiovascular events and a may have contributed to an increase in the incidence of end stage renal disease. This paper reviews the rationale for achieving lower blood pressure goals (i.e., less than 130/85 mm Hg) in people with diabetes and/or renal disease. It also provides an approach as to how to achieve these lower goal blood pressures with a minimum of side effects. Lastly, the use of fixed dose combinations is discussed as a method to improve compliance. In brief, patients with diabetes or renal disease will require an average of 2.6-4.3 different antihypertensive medications to achieve these lower blood pressure targets. The number of medications is a function of the degree of renal insufficiency. If done appropriately, patients can consume these medications in 2 to maybe 3 pills per day. By achieving these lower blood pressure goals there is a good possibility of reducing morbidity as well as mortality from cardiovascular and renal disease. More recent reports document that it is more cost effective in these high risk groups to achieve levels of diastolic blood pressure of less than 85 mm Hg. (c)1999 by Le Jacq Communications, Inc.

Entities:  

Year:  1999        PMID: 11416606

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  15 in total

Review 1.  Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?

Authors:  S S Franklin
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

Review 2.  Renal protection in hypertensive patients: selection of antihypertensive therapy.

Authors:  René R Wenzel
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.

Authors:  Domenic A Sica
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Choices and goals in the treatment of the diabetic hypertensive patient.

Authors:  E Basta; G Bakris
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

5.  Lipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetes.

Authors:  M Sherlock; D Mylotte; J Mac Mahon; K B Moore; C J Thompson
Journal:  Ir J Med Sci       Date:  2006 Oct-Dec       Impact factor: 1.568

Review 6.  Evolving strategies for the use of combination therapy in hypertension.

Authors:  Alan H Gradman; Celso Acevedo
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

Review 7.  Role of angiotensin II type 1 receptor antagonists in the treatment of hypertension in patients aged >or=65 years.

Authors:  Alan H Gradman
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 8.  Current concepts of pharmacotherapy in hypertension: combination calcium channel blocker therapy in the treatment of hypertension.

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Sep-Oct       Impact factor: 3.738

Review 9.  Improving patient compliance: a major goal in the management of hypertension.

Authors:  Joel M Neutel; David H G Smith
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Mar-Apr       Impact factor: 3.738

Review 10.  Dispelling the myth of "aggressive" antihypertensive therapy.

Authors:  Elizabeth O Ofili
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.